Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1. | Zendy

Sumit Chakraborty | Zendy; Kyu Y. Rhee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1.

Author(s) -

Sumit Chakraborty,

Kyu Y. Rhee

Publication year - 2015

Publication title -

cold spring harbor perspectives in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.853

H-Index - 105

eISSN - 2472-5412

pISSN - 2157-1422

DOI - 10.1101/cshperspect.a021147

Subject(s) - mechanism (biology) , tuberculosis , drug , medicine , drug resistance , intensive care medicine , drug development , pharmacology , biology , epistemology , pathology , genetics , philosophy

Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-infectives research. However, only one new TB drug has entered clinical practice in the past 40 years while drug resistance threatens to further destabilize the pandemic. Here, we review a brief history of TB drug development, focusing on the evolution of mechanism(s)-of-action studies and key conceptual barriers to rational, mechanism-based drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research